Do-Coop Technologies Announces the Publication of the First Peer-Reviewed Scientific Paper about Neowater, its Proprietary Water-Based Nanotechnology.

OR-YEHUDA, Israel -- Do-Coop Technologies Ltd., a privately held corporation based in Israel, announced today that the Journal of Electrochemical Deposition has published the scientific paper "The effect of rf-irradiation on electrochemical deposition and its stabilization by nanoparticle doping." The paper by leading physicists measured and studied some of the unique physical effects of Neowater, its proprietary water-based nanotechnology in a well-known system. The paper provides strong scientific evidence and validation that Neowater's uniqueness is due to quantum physical effects rather than to chemical or nanoparticles-related properties.

About Neowater

Neowater is an enabling technology that is based on breakthrough water-based nanotechnology. Unlike traditional, dry nanotechnology, which focuses on a nanoparticle end product, Neowater builds upon the unique properties of nanoparticles to modify the physical properties of water molecules around them.

This technology, developed in Israel, produces water whose physical properties mimic that of intracellular water using inorganic, insoluble crystals introduced in water in a patented process. Neowater, with its stable system of largely hydrated nanoparticles, like non-ionic detergent derived micelles, reduces the entropy of aqueous solutions. In addition, by design, since it exhibits both hydrophilic and hydrophobic properties it can be used as a unique solvent replacement.

First Peer-Reviewed Scientific Paper

Biotech and pharmaceutical companies have within their portfolios a significant amount of compounds and drugs which have been proven effective in vitro, yet they are very insoluble and thus unusable, such as novel cancer therapeutic drugs. Other compounds which are good drug candidates are too soluble, or they are prone to hydrolysis, both rendering them ineffective. While these companies are experts at screening and finding effective compounds, and they have invested millions in this effort, they often lack the expertise to overcome these challenging technological barriers and release these compounds to the market. Neowater technology allows such companies to capture the real value of otherwise valueless portfolios.

Using Neowater, biotech and pharma companies can solvate their valuable compounds, enhancing both their stability and bioavailability, and thus can extend and protect their intellectual property and investments.

"However, Biotech and Pharma companies have repeatedly asked us for peer-reviewed scientific studies to help them understand how Neowater might be different from regular water. This paper, by renowned physicists from Tel Aviv University, is the first in a series of papers that will be published by leading scientists and that will be covering various aspects and applications of Neowater.

"This initial paper clearly shows the scientific community that the properties of Neowater are not chemical but rather physical in nature. It also postulates that the role of the nanoparticles within Neowater is one of stabilizing the gas nanobubbles and water molecules around them. Lastly, the paper demonstrates that the effects of Neowater are physical by definition, and are energetically related to quantum physics events at room temperature.

"In parallel to the work on scientific publications, we have begun a regulatory review of Neowater, and we have also designed, built and approved the first cGMP-compliant Neowater manufacturing plant, which is located in Israel. These milestones, altogether mean that our pharma customers now have a complete technology package, and can continue to confidently formulate their compounds with Neowater and also begin to understand why Neowater is able to replace organic solvents although Neowater is made of pure water," said Eran Gabbai, founder, President and CTO of Do-Coop Technologies, and the inventor of Neowater technology.

The scientific paper by Y. Katsir, L. Miller, Y. Aharonov and E. Ben Jacob has been accepted to be presented as a poster presentation on Monday, October 8, 2007 at 16:00h in the Exhibit Hall, Concourse Level in the Poster Session of the 212th Meeting of the Electrochemical Society. The Meeting will be held at the Hilton Washington in Washington, DC, October 7 - October 12, 2007. (http://www.electrochem.org).

More details can be found in Do-Coop's web site at http://www.docoop.com/.